Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

NYSE:PFE - Post Discussion

Pfizer Inc > Pfizer to apply for COVID-19 vaccine approval in Japan on Fr
View:
Post by Humanist on Dec 17, 2020 1:38pm

Pfizer to apply for COVID-19 vaccine approval in Japan on Fr

Pfizer to apply for COVID-19 vaccine approval in Japan on Friday - Kyodo

12/17/2020 1:17 PM ET • Reuters

 

 


Dec 17 (Reuters) - Drugmaker Pfizer Inc will request for an approval of its COVID-19 vaccine in Japan on Friday, Kyodo News reported, citing sources familiar with the move.

The Japanese government has a supply deal with Pfizer for 120 million vaccine doses. (https://bit.ly/2K4ntRV)

The United States and Britain have already begun administering the vaccine made by Pfizer and German partner BioNTech. (Reporting by Dania Nadeem in Bengaluru; Editing by Shounak Dasgupta)
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Dealroom for high-potential pre-IPO opportunities